Xilio Therapeutics Inc
XLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.69M
Close$
$17.53
84.7% upside
Current Fair Value
84.7% upsideUndervalued by 84.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $60.69 Million |
|---|---|
| Enterprise Value | $-46,445,467.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.19 |
| Beta | -0.12 |
| Outstanding Shares | 19,404,688 |
Return
| Return on Equity | -7.67% |
|---|---|
| Return on Assets | -3.59% |
| Return on Invested Capital | -14.96% |
Valuation & Multiples
| P/E Ratio | -6.19 |
|---|---|
| PEG | 10.36 |
| Price to Sales | 3.16 |
| Price to Book Ratio | 3.16 |
| Enterprise Value to Revenue | -0.72 |
| Enterprise Value to EBIT | 2.59 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | -0.62 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$12.72 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$4.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.60%▼ 1.79% |
|---|---|
| Total Invested | $22.03M▼ 13.38% |
| Investors Holding | 24▼ 13.00% |
ESG Score
No data